1 / 22

생명과학부 석사 1 년차 김 원

Proteome analysis and its impact on the discovery of serological tumor markers Terence C.W.Poon, Philip J. Johnson Clinica Chimica Acta 313 (2001) 231-239. 생명과학부 석사 1 년차 김 원. 1. Introduction 2. Concept of proteome and proteomics 3. Advances in proteome analysis

hashim
Download Presentation

생명과학부 석사 1 년차 김 원

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Proteome analysis and its impact on the discovery of serological tumor markersTerence C.W.Poon, Philip J. JohnsonClinica Chimica Acta 313 (2001) 231-239 생명과학부 석사 1년차 김 원

  2. 1. Introduction • 2. Concept of proteome and proteomics • 3. Advances in proteome analysis • 4. What are tumor markers? • 5. Hepatocellular carcinoma as a model tumor for tumor marker discovery 5.1 Current clinical tools for diagnosis and for monitoring treatment response 5.2 Discovery of novel tumor markers by proteome analysis of sera • 6. Future Prospects • 7. Conclusion

  3. 1. Introduction • Tumor marker – screening, diagnosis, staging, prognosis, monitoring • There is little consensus on their clinical use -> We need better methods for discovering Sensitive and specific markers

  4. 2. Concept of proteome and proteomics • Proteome : Entire protein complement • Proteome is dynamic : change with time and according to physiological • Proteomics:‘the study of protein properties’ (expression level, post-translational modification, interaction) • Proteomic study 1)structure : protein-protein interaction 2)quantitative regulation : expression level

  5. 3. Advances in proteome analysis

  6. History of 2D PAGE • 1970s (by O’Farrel) -> 2D PAGE • 1980s -> Immobilized pH gradients -> Consistent,reproducible • Recent -> High sensitivity stain, narrow pI range

  7. Merits of 2D PAGE • Separation of a large number of proteins • Quantitative information(by intensity of the spots) • Information on post-translational modifications, glycosylation, phosphorylation

  8. Use of 2D PAGE • Identify with MALDI-TOF • Comparison under different experimental conditions -> especially useful in finding disease-associated proteins • We have not databases of full-length sequences of a large percentage of human proteins -> unidentified proteins -> Q-TOF MS for amino acid sequencing

  9. 4. What are tumor markers? • Biomolecules that can be measured quantitatively in body tissues or fluids • Can be clinically useful in patients with malignancies • Need for screening, diagnosis, staging, prognosis, monitoring treatment response, detection of tumor recurrence • Highly specific for a single type of tumor -> rare->specific to tumor cells but, cancer type Ex) AFP (alpha-fetoprotein) : HCC(mainly), testicular cancer, ovarian cancer(frequently) • Detect in blood or tissue section

  10. 5. Hepatocellular carcinoma as a model tumor for tumor marker discovery

  11. 5.1 Current clinical tools for diagnosis and for monitoring treatment response • AFP is the conventional marker for HCC * level up : 80% of patients with HCC • Most HCCs arise in patients with coexisting chronic liver disease -> limits the use of AFP for early detection of HCC • Current standard method -> Imaging Technique -> difficult ( < 2cm nodule) We need general method to detect novel marker for the diagnosis and monitoring

  12. 5.2 Discovery of novel tumor markers by proteome analysis of sera • By analysing and comparing the proteomes of cancer and normal tissues or cells, We found the disease-associated proteins (2D PAGE) ->They can also be detected in biological fluids (plasma or serum) • Direct analysis on biological fluids such as urine or serum -> compare samples from cancer patients and healthy controls

  13. Typical example HCC Normal About 20 spots detected

  14. Disappearance of this AFP strongly indicates that it is a protein specifically released by the HCC Studies of more patient and control specimens ㅡ> This will be potential tumor marker

  15. Antibody Detection Method

  16. SCC Normal

  17. Cystectomy

  18. 6. Future prospects( Other separation technique ) • A. HPLC 1D : size-exclusion chromatography 2D : reverse-phase HPLC 1D : size-exclusion HPLC 2D : capillary isoelectric focusing faster sample separation, higher throughput, automation • B. Direct analysis of unseparated protein mixture : protease digestion -> LC -> tandem MS -> limited by the current MS technology (only simple protein mixture) ->next generation

  19. 7. Conclusion • The combination of 2D PAGE and MS is the most widely used strategy for proteome analysis • Proteome analysis on sera from cancer patients and control subjects has been shown to be capable of identifying novel tumor markers -> not sufficient • Automatic high-throughput analysis and large dynamic range -> can find high sensitivity & specificity novel tumor marker

  20. Problems • Heterogeneity of biopsy materials • Technical problems Separation Focusing of some proteins • Large dynamic range of protein expression • Lack of suitable procedures for quantitating protein changes • Better image analysis system • Databases

More Related